Open AccessUsing tranexamic acid for an additional 24 hours postoperatively in hip and knee arthroplasty saves money: a cost analysis from the TRAC-24 randomized control trial
Author(s) -
Paul N. Karayiannis,
Ashley Agus,
Leanne Bryce,
Janet Hill,
David Beverland
Publication year - 2022
Publication title -
bone and joint open
Language(s) - English
Resource type - Journals
ISSN - 2633-1462
DOI - 10.1302/2633-1462.37.bjo-2021-0213.r1
Subject(s) - tranexamic acid , randomized controlled trial , medicine , arthroplasty , trac , hip arthroplasty , surgery , computer science , blood loss , programming language
Tranexamic acid (TXA) is now commonly used in major surgical operations including orthopaedics. The TRAC-24 randomized control trial (RCT) aimed to assess if an additional 24 hours of TXA postoperatively in primary total hip (THA) and total knee arthroplasty (TKA) reduced blood loss. Contrary to other orthopaedic studies to date, this trial included high-risk patients. This paper presents the results of a cost analysis undertaken alongside this RCT.